(from CNN)
On Wednesday, US drugmaker Eli Lilly announced that the Phase 3 clinical trial of its drug solanezumab did not progress as planned.
“Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo,” the company said in a statement.
In a statement, Lilly’s chairman, president and CEO John C. Lechleiter said the company was “disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer’s disease.”
Read the full article on CNN.
Doctor Dementia and the Dementia Adventure 
The most promising news for Alzheimer and Dementia came from a recent examination of the brains of very old nuns in the USA that had died aged ninety or over. They found that though they had full blown Alzheimer they were as bright as pins till they died of other causes. This means that so far exercising the brain with activities as these nuns do is for the time being is the best remedy.
LikeLike